{"id":827478,"date":"2025-03-19T08:34:00","date_gmt":"2025-03-19T12:34:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-announces-late-breaker-and-new-data-presentations-at-the-american-college-of-cardiologys-annual-scientific-session\/"},"modified":"2025-03-19T08:34:00","modified_gmt":"2025-03-19T12:34:00","slug":"tenaya-therapeutics-announces-late-breaker-and-new-data-presentations-at-the-american-college-of-cardiologys-annual-scientific-session","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-announces-late-breaker-and-new-data-presentations-at-the-american-college-of-cardiologys-annual-scientific-session\/","title":{"rendered":"Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology\u2019s Annual Scientific Session"},"content":{"rendered":"

\nLate Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK\u2122-1 Phase 1b\/2 Clinical Trial of TN-201
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that new clinical and disease burden data pertaining to the company\u2019s MYBPC3<\/em>-associated hypertrophic cardiomyopathy (HCM) program will be presented at the upcoming American College of Cardiology\u2019s Annual Scientific Session being held March 29-31, 2025 in Chicago, IL.<\/p>\n

Tenaya is advancing TN-201, an AAV9-based gene therapy for the potential treatment of MYBPC3<\/em>-associated HCM, a condition caused by insufficient levels of myosin-binding protein C (MyBP-C). As part of the late-breaking Clinical and Investigative Horizons session on Monday, March 31, data from the first cohort of adult patients enrolled in the MyPEAK-1 Phase 1b\/2 clinical trial will be featured. Building on early encouraging data shared in December 2024, the presentation at ACC will include results from one-year assessments of the first two patients to receive TN-201 gene therapy, and baseline biopsy and six-month assessments from the third patient in the 3E13 vg\/kg cohort. These data will be presented by Milind Desai, M.D., M.B.A, Haslam Family Endowed Chair in Cardiovascular Medicine, Vice Chair, Heart Vascular Thoracic Institute, Director of the Hypertrophic Cardiomyopathy Center at the Cleveland Clinic, and an investigator for the MyPEAK-1 Phase 1b\/2 clinical trial.<\/p>\n

A poster presentation on Sunday, March 30, will detail findings from SHaRe (Sarcomeric Human Cardiomyopathy Registry), describing differences in disease burden among adults with HCM caused by MYBPC3<\/em> mutations.<\/p>\n

Details of the presentations are as follows:<\/p>\n

\n Sunday, March 30, 2025<\/em>\n <\/p>\n